MED Company Profile and Key Details

Medifast, Inc. last paid a dividend of 0 per share, this equals a trailing yield of roughly 17.57%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $501.46. This means the shares are trading below this model’s fair value.

The latest quarter delivered EPS of -$0.21. The next quarter is forecast at -$0.52. Next year's EPS is expected at -$43.21. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $15.00. The high target offers 44.79% upside. The low target suggests 44.79% downside. The mean target is $15.00. This offers 44.79% upside. Medifast, Inc. earnings surprise history is a mixed track record. The quarter that ended November 03, 2025, missed forecasts by 1957.1%. The prior quarter beat by -113.33%. Over the last six quarters, Apple has recorded several small beats. These include 155.56% in August 05, 2024.

MED has shown mixed momentum, losing -0.26% over the past week and -9.75% over the past quarter, though year-to-date performance is up 9.18%. Short-term trend indicators are bullishly aligned (SMA20 -4.41%, SMA50 -7.02%, SMA200 -17.93%). The stock’s 14-day RSI is 37.36 (weak momentum), while the ATR of 0.44 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -32.54% below its high and over 3.27% above its low. Average 10-day trading volume of 229.10 thousand shares is below the 3-month average of 261.91 thousand, indicating normal recent market interest.

Medifast, Inc. has 10.99 million shares outstanding. The public float is 9.15 million shares, elevated short interest at 21.41% of float. This equals 2.29 million shares. The short ratio is 11.35 days. Institutional investors hold 82.62% of the float. Insiders own 3.2%. Chard Daniel R holds 17.68 thousand shares, Hoer Michael A. has 8.38 thousand shares and BYRNES KEVIN G has 8.15 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Medifast, Inc. (NYSE:MED) closed at $10.36 USD, gaining $0.26 (2.57%) from the previous close of $10.10. The stock is currently mid-range between its 52-week high and low $9.22 and $15.46. With a market capitalization of about $113.87 million, Medifast, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 260.74 thousand shares, volume is running light vs its 52-week average. Headquartered in Baltimore, MD, Medifast, Inc. operates in the Consumer Cyclical sector and the Personal Products & Services industry. Led by CEO Daniel R. Chard, the company employs approximately 504 people and listed since December 30, 1993. Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.

Medifast, Inc. trades at a P/E ratio of -6.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.3 and a price-to-book ratio of 0.57 suggesting the stock is closer to book value. The P/FCF stands at 91.17, also above market averages.

Our AI price prediction model suggests that Medifast, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.12%, with price expected at $9.83 by April 16, 2026, within a range of $9.55 to $10.13 3-Month Outlook: Projected fall of -6.66%, reaching $9.67 by July 01, 2026, with a range of $9.11 to $10.14. 1-Year Outlook: Projected loss of -31.18%, with price at $7.13 by April 02, 2027, within a range of $4.90 to $7.44.

Medifast, Inc. (NYSE:MED) shares are flat 9.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Medifast, Inc. trading at a premium to the broader market with a P/E of -6.1. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $79.54, suggesting 667.76% upside. Our AI forecast model points to short-term weakness (-5.12% over two weeks), a medium-term fall (-6.66% over three months), and a longer-term loss (-31.18% over one year), with expected trading ranges indicating moderate volatility.